Penumbra, Inc. (NYSE:PEN) EVP Robert D. Evans sold 2,859 shares of Penumbra stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $90.00, for a total value of $257,310.00. Following the sale, the executive vice president now directly owns 11,704 shares of the company’s stock, valued at approximately $1,053,360. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Penumbra, Inc. (NYSE PEN) traded down 0.45% during midday trading on Friday, hitting $88.90. The company had a trading volume of 153,383 shares. The company has a market cap of $3.00 billion, a price-to-earnings ratio of 600.68 and a beta of 0.09. The firm has a 50-day moving average price of $85.75 and a 200-day moving average price of $84.49. Penumbra, Inc. has a 12 month low of $56.05 and a 12 month high of $91.00.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $80.60 million for the quarter, compared to the consensus estimate of $77.16 million. Penumbra had a negative return on equity of 2.58% and a negative net margin of 2.78%. The firm’s quarterly revenue was up 23.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.01 EPS. Equities analysts anticipate that Penumbra, Inc. will post ($0.21) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Penumbra, Inc. (PEN) EVP Sells $257,310.00 in Stock” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/22/penumbra-inc-pen-evp-sells-257310-00-in-stock.html.

A number of research firms recently commented on PEN. BidaskClub downgraded Penumbra from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Canaccord Genuity reaffirmed a “buy” rating and set a $100.00 target price (up previously from $94.00) on shares of Penumbra in a report on Wednesday, August 9th. Zacks Investment Research downgraded Penumbra from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $96.00 target price on shares of Penumbra in a report on Friday, June 16th.

A number of large investors have recently added to or reduced their stakes in the stock. Lord Abbett & CO. LLC grew its stake in Penumbra by 5.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 1,093,621 shares of the company’s stock worth $95,965,000 after buying an additional 53,109 shares during the last quarter. Verition Fund Management LLC purchased a new position in Penumbra during the 2nd quarter worth approximately $213,000. Ameritas Investment Partners Inc. grew its stake in Penumbra by 10.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock worth $226,000 after buying an additional 250 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Penumbra by 14.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,544 shares of the company’s stock worth $1,979,000 after buying an additional 2,897 shares during the last quarter. Finally, State Street Corp grew its stake in Penumbra by 13.2% during the 2nd quarter. State Street Corp now owns 579,911 shares of the company’s stock worth $50,887,000 after buying an additional 67,441 shares during the last quarter. Hedge funds and other institutional investors own 70.93% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.